- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Rani Therapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 5 | SEC Filings | ||
| 20.03. | Rani Therapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 20.03. | Recap: Rani Therapeutics Holdings Q4 Earnings | 1 | Benzinga.com | ||
| 20.03. | Rani Therapeutics GAAP EPS of -$0.27 beats by $0.04 | 1 | Seeking Alpha | ||
| 20.03. | Rani Therapeutics Holdings, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.03. | Rani Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update | 55 | GlobeNewswire (Europe) | - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin... ► Artikel lesen | |
| 19.03. | Earnings Outlook For Rani Therapeutics Holdings | 1 | Benzinga.com | ||
| 15.03. | Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results | 1 | GlobeNewswire (USA) | ||
| 05.02. | Rani Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.12.23 | Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist | 198 | GlobeNewswire (Europe) | - Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study - - Preclinical data support the potential for the RaniPill platform to... ► Artikel lesen | |
| 14.12.23 | Rani Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.23 | Rani Therapeutics CEO discloses purchase of 10K shares | 2 | Seeking Alpha | ||
| 06.12.23 | Rani Therapeutics CEO Talat Imran purchases 5,000 shares | 2 | Seeking Alpha | ||
| 01.12.23 | Rani Therapeutics says CEO Imran buys 20K class A shares | 1 | Seeking Alpha | ||
| 09.11.23 | Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05 | 2 | Seeking Alpha | ||
| 09.11.23 | Analyst Ratings for Rani Therapeutics Holdings | 1 | Benzinga.com | ||
| 08.11.23 | Rani Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.11.23 | Rani Therapeutics Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.11.23 | Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update | 134 | GlobeNewswire (Europe) | - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,65 | -0,18 % | BioNTech Komplettabsturz! | Für BioNTech-Aktionäre kommt es heute knüppeldick. Denn der Kurs notiert rund drei Prozent in der Verlustzone. Damit verbilligt sich der Wert jetzt auf nur noch 80,00 EUR. Ist das nur ein kurzzeitiger... ► Artikel lesen | |
| VALNEVA | 3,590 | -0,72 % | Original-Research: Valneva (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Valneva Unternehmen: Valneva ISIN: FR0004056851 Anlass der Studie: Update... ► Artikel lesen | |
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,470 | +1,71 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,800 | -2,70 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| TREVENA | 0,378 | +5,74 % | TREVENA INC - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| BAVARIAN NORDIC | 19,955 | -0,57 % | Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such | ||
| BELLEROPHON THERAPEUTICS | 0,001 | -100,00 % | Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology; Athersys, Inc.; Borqs Technologies; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition; Evelo Biosciences ... | NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.'s securities were suspended on... ► Artikel lesen | |
| AFFIMED | 4,940 | +8,10 % | Affimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,839 | 0,00 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| PHIO PHARMACEUTICALS | 0,671 | 0,00 % | Phio Pharmaceuticals Corp.: Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells | -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma... ► Artikel lesen | |
| IMMUNITYBIO | 5,152 | +14,49 % | Pre-market Movers: Abeona Therapeutics, HWH International, ImmunityBio, Hibbett, AGBA Group | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.55 A.M. ET).In the Green HWH International Inc. (HWH) is up over 42% at $1.83.
ImmunityBio... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 2,053 | +0,98 % | Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 | ||
| BIOXCEL THERAPEUTICS | 2,552 | +0,95 % | BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE... ► Artikel lesen |
RANI THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
